Rafferty Asset Management
NKTR icon

Rafferty Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Rafferty Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Buy
+3,499
New +$256K ﹤0.01% 1056
2023
Q1 		– Sell
-929
Closed -$31.5K – 1159
2022
Q4 		$31.5K Sell
929
-1,312
-59% -$63.5K ﹤0.01% 1117
2022
Q3 		$108K Sell
2,241
-2,519
-53% -$150K ﹤0.01% 1121
2022
Q2 		$271K Buy
4,760
+3,202
+206% +$202K ﹤0.01% 944
2022
Q1 		$126K Sell
1,558
-58
-4% -$8.58K ﹤0.01% 1161
2021
Q4 		$327K Buy
1,616
+512
+46% +$111K ﹤0.01% 1136
2021
Q3 		$298K Buy
1,104
+371
+51% +$89.2K ﹤0.01% 1129
2021
Q2 		$189K Buy
+733
New +$203K ﹤0.01% 1233
2021
Q1 		– Sell
-1,113
Closed -$284K – 1168
2020
Q4 		$284K Buy
+1,113
New +$288K ﹤0.01% 835
2020
Q3 		– Sell
-1,222
Closed -$424K – 1015
2020
Q2 		$424K Buy
+1,222
New +$381K 0.01% 748
2020
Q1 		– Sell
-1,277
Closed -$413K – 740
2019
Q4 		$413K Sell
1,277
-418
-25% -$121K 0.01% 721
2019
Q3 		$463K Buy
+1,695
New +$622K 0.01% 675

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's NKTR Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 3,499 shares worth $244K. The stake represents ﹤0.01% of the portfolio and ranks #1056 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in NKTR as recently as Q4 2022.

Rafferty Asset Management first reported a position in NKTR in Q3 2019 and has held it in 12 quarters since. The position peaked at $463K in Q3 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Rafferty Asset Management held 3,499 shares of Nektar Therapeutics worth $244K as of Q2 2026.
  • Nektar Therapeutics was a new Rafferty Asset Management position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1056 holding.
  • Rafferty Asset Management first reported a position in Nektar Therapeutics in Q3 2019 and has held it in 12 quarters since.
  • Rafferty Asset Management's Nektar Therapeutics position peaked at $463K in Q3 2019.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.